Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 

The rules state that the following are covered indications for Intravenous Immunoglobulin (IVIG): 
 
   - The treatment of primary immunodeficiency syndromes associated with defects in humoral immunity to 
replace or boost immunoglobulin G (IgG) 
   - The treatment of idiopathic thrombocytopenic purpura (ITP) when a rapid rise in the platelet count is 
required such as prior to surgery, to control excessive bleeding, or to defer or avoid splenectomy 
   - Treatment of Kawasaki disease, in conjunction with aspirin 
   - Prevention of recurrent bacterial infections in patients with hypogammaglobulinemia associated with B-cell 
chronic lymphocytic leukemia (CLL) 
   - Decreasing risk of acute graft-vs.-host disease, associated interstitial pneumonia, and infections after bone 
marrow transplant in the first 100 days after transplantation 
   - Reducing the risk of severe bacterial infections in human immunodeficiency virus (HIV) infected children 
with a CD4 count of greater than 200 to 400 
   - Second-line treatment of dermatomyositis 
   - The treatment of adults with Guillain-Barr syndrome diagnosed within the first 2 weeks of illness 
   - Treatment of hyperimmunoglobulinemia E syndrome and Lambert-Eaton myasthenic syndrome (LEMS) 
   - Treatment of multifocal motor neuropathy (MMN) 
   - Treatment of relapsing-remitting multiple sclerosis 
   - Treatment of chronic parvovirus B19 infection and severe anemia associated with bone marrow suppression 
and pure red cell aplasia 
   - Treatment of progressive pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous 
membrane pemphigoid, and epidermolysis bullosa acquisita in patients that have failed conventional treatment 
and patients in whom conventional therapy is otherwise contraindicated 
   - For coverage criteria of Autoimmune Mucocutaneous Blistering Diseases, please see CMS Internet-Only 
Manual, Pub. 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 4, 250.3 
   - Treatment of stiff person syndrome 
   - Treatment of Myasthenia Gravis (MG) in patients who have profound, rapidly progressive and/or 
potentially life-threatening muscular weakness and are refractory to, or intolerant of cholinesterase inhibitors, 
corticosteroids and azathioprine 
   - The prevention and/or treatment of organ rejection in patients sensitized to living or cadaveric organ donors 
    Schonlein-Henoch 
   - Treatment of Paraneoplastic Visual Loss 
   - Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in patients meeting the 
necessary criteria 
   - Treatment of Multiple Myeloma for the prevention of life-threatening infections due to reduced gamma 
globulins 
 
You can find this rule in the Local Coverage Determination (LCD): Intravenous Immunoglobulin (IVIG) 
(L34580). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.